Evaluation of treatment strategies for patients with stage IIIA non-small cell lung cancer in the immunotherapy era by Amy Alabaster, Jeffrey B. Velotta, Haley I. Tupper, Mark S. Walker, Yanina Natanzon

Subjects: Get full text

Time trends in mechanical thrombectomy (2017–2021): do real-world data reflect advances in evidence? by Christoph Riegler, Christoph Riegler, Viktoria Rücker, Regina von Rennenberg, Regina von Rennenberg, Kerstin Bollweg, Kerstin Bollweg, Bastian Cheng, Anna C. Alegiani, Fabian Flottmann, Marlena Schnieder, Marielle Ernst, Waltraud Pfeilschifter, Waltraud Pfeilschifter, Waltraud Pfeilschifter, Christoffer Kraemer, Ruben Mühl-Benninghaus, Steffen Tiedt, Steffen Tiedt, Lars Kellert, Hanna Zimmermann, Felix J. Bode, Felix J. Bode, Gabor C. Petzold, Gabor C. Petzold, Franziska Dorn, Jörg Berrouschot, Albrecht Bormann, Kathleen Bernkopf, Silke Wunderlich, Tobias Boeckh-Behrens, Martina Petersen, Lars Udo Krause, Stephan Lowens, Heinrich J. Audebert, Heinrich J. Audebert, Eberhard Siebert, Peter U. Heuschmann, Peter U. Heuschmann, Peter U. Heuschmann, Christian H. Nolte, Christian H. Nolte, Christian H. Nolte, Christian H. Nolte

Subjects: Get full text

Brief report: impact of consolidation durvalumab on unresectable non-small cell lung cancer with driver mutations by Jason C.S. Ho, K.M. Cheung

Subjects: Get full text

Real-world data of dacomitinib as first-line treatment for patients with EGFR-mutant non-small-cell lung cancer by Ji Eun Shin, Hyun Ae Jung, Sehhoon Park, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Myung-Ju Ahn, Byoung Yong Shim

Subjects: Get full text